Alcoholic Hepatitis: Prognostic Models and Treatment

Gastroenterology Clinics of North America

Volumn 40, Issue 3, 2011, Pages 611-639

  Singal, Ashwani K ^a   Shah, Vijay H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alcoholic hepatitis; Corticosteroids; Liver transplantation; Pentoxifylline; Tumor necrosis factor

Indexed keywords

ACAMPROSATE; ACETYLCYSTEINE; ALBUMIN; ANTIBIOTIC AGENT; ANTIOXIDANT; BACLOFEN; BENZODIAZEPINE; BILIRUBIN; CORTICOSTEROID; DIURETIC AGENT; ETANERCEPT; INFLIXIMAB; LORAZEPAM; MERCAPTOPURINE; METHYLPREDNISOLONE; MIDODRINE; NALTREXONE; OCTREOTIDE; OXAZEPAM; PENTOXIFYLLINE; PHENOBARBITAL; PLACEBO; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; PROPOFOL; RIFAXIMIN; TERLIPRESSIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ACUTE DISEASE; ADJUVANT THERAPY; AGE BILIRUBIN INR CREATININE SCORE; ALCOHOL ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOL WITHDRAWAL; ASCITES; BACTERIAL PERITONITIS; CHILD TURCOTTE PUGH SCORE; CHRONIC LIVER DISEASE; DISCRIMINANT FUNCTION INDEX; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; GLASGOW ALCOHOLIC HEPATITIS SCORE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; INFECTION; INTERMETHOD COMPARISON; LILLE SCORE; MEDICAL ETHICS; MODEL FOR END STAGE LIVER DISEASE SCORE; NONHUMAN; PARACENTESIS; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SINGLE DRUG DOSE; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UNSPECIFIED SIDE EFFECT; VARICOSIS; VARIX BLEEDING; VEIN LIGATION;

GASTROINTESTINAL AGENTS; HEPATIC INSUFFICIENCY; HEPATITIS, ALCOHOLIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALNUTRITION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TEMPERANCE;

EID: 80052356139     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2011.06.008     Document Type: Review

References (142)

1. Lucey M.R., Mathurin P., Morgan T.R. Alcoholic hepatitis. N Engl J Med 2009, 360:2758-2769.
2. Naveau S., Giraud V., Borotto E., et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997, 25:108-111.
3. Maddrey W.C., Boitnott J.K., Bedine M.S., et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978, 75:193-199.
4. Carithers R.L., Herlong H.F., Diehl A.M., et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989, 110:685-690.
5. Mathurin P., Mendenhall C.L., Carithers R.L., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002, 36:480-487.
6. McCullough A.J., O'Connor J.F. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998, 93:2022-2036.
7. Tripodi A., Caldwell S.H., Hoffman M., et al. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007, 26:141-148.
8. Kulkarni K., Tran T., Medrano M., et al. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 2004, 38:453-459.
9. Child C.G., Turcotte J.G. Surgery and portal hypertension 1964, WB Saunders, Philadelphia.
10. Said A., Williams J., Holden J., et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004, 40:897-903.
11. Srikureja W., Kyulo N.L., Runyon B.A., et al. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005, 42:700-706.
12. Jeong J.Y., Sohn J.H., Son B.K., et al. [Comparison of model for end-stage liver disease score with discriminant function and child-Turcotte-Pugh scores for predicting short-term mortality in Korean patients with alcoholic hepatitis]. Korean J Gastroenterol 2007, 49:93-99.
13. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
14. Kamath P.S., Kim W.R. The model for end-stage liver disease (MELD). Hepatology 2007, 45:797-805.
15. Dunn W., Jamil L.H., Brown L.S., et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005, 41:353-358.
16. Sheth M., Riggs M., Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002, 2:2.
17. Vaa B.E., Asrani S.K., Dunn W., et al. Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin Proc 2011, 86:37-42.
18. Kamath P.S., Kim W.R. Is the change in MELD score a better indicator of mortality than baseline MELD score?. Liver Transpl 2003, 9:19-21.
19. Verma S., Ajudia K., Mendler M., et al. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006, 51:1637-1643.
20. Zapata-Irrison L., Jurado-Nunez J., Altamirano-Gomez J. [do MELD or Maddrey?. Comparison of 2 forecasting models in patients with hepatitis toxic alcohol. Rev Gastroenterol Mex 2008, 73:57-62.
21. O'Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology 2010, 51:307-328.
22. Forrest E.H., Evans C.D., Stewart S., et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005, 54:1174-1179.
23. Forrest E.H., Morris A.J., Stewart S., et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007, 56:1743-1746.
24. Dominguez M., Rincon D., Abraldes J.G., et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008, 103:2747-2756.
25. Mathurin P., Abdelnour M., Ramond M.J., et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003, 38:1363-1369.
26. Nguyen-Khac E.T.T., Piquet M.A., Benferhat S., et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N-acetylcysteine (C+NAC) versus corticoids alone (C): a multicenter, randomized, controlled trial. J Hepatology 2010, 52(Suppl 1):S38.
27. Louvet A., Naveau S., Abdelnour M., et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007, 45:1348-1354.
28. Louvet A.A., Wartel F., O'Grady J.G., et al. A response guided therapy for a better management of patients with severe alcoholic hepatitis treated with corticosteroids. Hepatology 2010, 52(4 Suppl):1109A.
29. Nguyen-Khac E.T.T., Piquet M.A., Benferhat S., et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N-acetylcysteine (C+NAC) versus corticoids alone (C): a multicenter, randomized, controlled trial. Hepatology 2009, 50(4 Suppl):346A.
30. Castel H., Moreno C., Antonini T.M., et al. Early transplantation improves survival of non-responders to steroids in severe alcoholic hepatitis: a challenge to the 6-month rule of abstinence. J Hepatology 2009, 52(Suppl 1):S13.
31. Louvet A.A., Diaz E., Wartel F., et al. Prognostic scores are efficient in patients with severe alcoholic hepatitis treated with corticosteroids: comparison of available models. Hepatology 2010, 52(4 Suppl):1108A-1109A.
32. Pessione F., Ramond M.J., Peters L., et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003, 23:45-53.
33. Morgan M.Y. The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol Suppl 1994, 2:335-343.
34. Tripodi S.J., Bender K., Litschge C., et al. Interventions for reducing adolescent alcohol abuse: a meta-analytic review. Arch Pediatr Adolesc Med 2010, 164:85-91.
35. Chung T., Martin C.S., Winters K.C. Diagnosis, course, and assessment of alcohol abuse and dependence in adolescents. Recent Dev Alcohol 2005, 17:5-27.
36. Garbutt J., Kranzler H., O'Malley S., et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005, 293:1617-1625.
37. Rosner S., Hackl-Herrwerth A., Leucht S., et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010, 9. CD004332.
38. Addolorato G., Leggio L., Ferrulli A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007, 370:1915-1922.
39. Garcia-Tsao G., Lim J.K. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009, 104:1802-1829.
40. Mendenhall C.L., Anderson S., Weesner R.E., et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984, 76:211-222.
41. Leevy C., Moroianu S. Nutritional aspects of alcoholic liver disease. Clin Liver Dis 2005, 9:67-81.
42. Mendenhall C.L., Moritz T.E., Roselle G.A., et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. JPEN J Parenter Enteral Nutr 1995, 19:258-265.
43. Cabré E., Rodríguez-Iglesias P., Caballería J., et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000, 32:36-42.
44. Mendenhall C.L., Moritz T.E., Roselle G.A., et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993, 17:564-576.
45. Morgan T.R., Moritz T.E., Mendenhall C.L., et al. Protein consumption and hepatic encephalopathy in alcoholic hepatitis. VA Cooperative Study Group #275. J Am Coll Nutr 1995, 14:152-158.
46. Plauth M., Cabre E., Riggio O., et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006, 25:285-294.
47. Helman R.A., Temko M.H., Nye S.W., et al. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971, 74:311-321.
48. Porter H.P., Simon F.R., Pope C.E., et al. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med 1971, 284:1350-1355.
49. Campra J.L., Hamlin E.M., Kirshbaum R.J., et al. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med 1973, 79:625-631.
50. Blitzer B.L., Mutchnick M.G., Joshi P.H., et al. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977, 22:477-484.
51. Shumaker J.B., Resnick R.H., Galambos J.T., et al. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978, 69:443-449.
52. Lesesne H.R., Bozymski E.M., Fallon H.J. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978, 74:169-173.
53. Depew W., Boyer T., Omata M., et al. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980, 78:524-529.
54. Theodossi A., Eddleston A.L., Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982, 23:75-79.
55. Mendenhall C.L., Anderson S., Garcia-Pont P., et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984, 311:1464-1470.
56. Ramond M.J., Poynard T., Rueff B., et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 20 1992, 326:507-512.
57. Daures J.P., Peray P., Bories P., et al. [Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis]. Gastroenterol Clin Biol 1991, 15:223-228.
58. Imperiale T.F., McCullough A.J. Do corticosteroids reduce mortality from alcoholic hepatitis?. A meta-analysis of the randomized trials. Ann Intern Med 1990, 113:299-307.
59. Rambaldi A., Saconato H.H., Christensen E., et al. Systematic review: glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008, 27:1167-1178.
60. Spahr L., Rubbia-Brandt L., Pugin J., et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 2001, 35:582-589.
61. Taieb J., Mathurin P., Elbim C., et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol 2000, 32:579-586.
62. Richardet J.D., Mal F., Roulot D., et al. Influence of corticosteroids (CS) on plasma cytokines concentrations in patients with severe alcoholic hepatitis (HA): results of a randomized study. J Hepatol 1993, 18:S75.
63. Mathurin P., Duchatelle V., Ramond M.J., et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996, 110:1847-1853.
64. Kendrick SF, Henderson E, Palmer J, et al. Theophylline improves steroid sensitivity in acute alcoholic hepatitis. Hepatology;52:126-31.
65. Louvet A., Wartel F., Castel H., et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009, 137:541-548.
66. Reuter B.K., Wallace J.L. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-alpha release. Am J Physiol 1999, 277:G847-G854.
67. McHutchison J.R., Draduesku J.O., et al. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991, 14:96A.
68. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.
69. Paladugu H., Sawant P., Dalvi L., et al. Role of pentoxifylline in treatment of severe acute alcoholic hepatitis-a randomized controlled trial. J Gastrenterol Hepatol 2006, 21:A459.
70. Sidhu S., Singla M., Bhatia K.L. Pentoxifyline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology 2006, 44:A373-A374.
71. Lebrec D., Dominique T., Oberti F., et al. Pentoxifylline for the treatment of patients with advanced cirrhosis. A randomized placebo controlled double blind trial. Hepatology 2007, 46:A249-A250.
72. De B.K., Gangopadhyay S., Dutta D., et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009, 15:1613-1619.
73. Louvet A., Diaz E., Dharancy S., et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008, 48:465-470.
74. Morgan T.R., McClain C.J. Pentoxifylline and alcoholic hepatitis. Gastroenterology 2000, 119:1787-1791.
75. Petrowsky H., Breitenstein S., Slankamenac K., et al. Effects of pentoxifylline on liver regeneration: a double-blinded, randomized, controlled trial in 101 patients undergoing major liver resection. Ann Surg 2010, 252:813-822.
76. Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology;138:1755-62.
77. Strieter R.M., Kunkel S.L., Bone R.C. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 1993, 21(10 Suppl):S447-S463.
78. Iimuro Y., Gallucci R.M., Luster M.I., et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997, 26:1530-1537.
79. Tilg H., Jalan R., Kaser A., et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003, 38:419-425.
80. Sharma P., Kumar A., Sharma B.C., et al. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol 2009, 50:584-591.
81. Spahr L., Rubbia-Brandt L., Frossard J.L., et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002, 37:448-455.
82. Naveau S., Chollet-Martin S., Dharancy S., et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004, 39:1390-1397.
83. Menon K.V., Stadheim L., Kamath P.S., et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004, 99:255-260.
84. Boetticher N.C., Peine C.J., Kwo P., et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008, 135:1953-1960.
85. Yamada Y., Kirillova I., Peschon J.J., et al. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A 18 1997, 94:1441-1446.
86. Hajeer A.H., Hutchinson I.V. TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech 2000, 50:216-228.
87. Yamada Y., Fausto N. Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor. Am J Pathol 1998, 152:1577-1589.
88. Akerman P., Cote P., Yang S.Q., et al. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol 1992, 263:G579-G585.
89. Dey A., Cederbaum A.I. Alcohol and oxidative liver injury. Hepatology 2006, 43(2 Suppl 1):S63-S74.
90. Loguercio C., Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 2003, 34:1-10.
91. Phillips M., Curtis H., Portmann B., et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis-a randomised clinical trial. J Hepatol 2006, 44:784-790.
92. Stewart S., Prince M., Bassendine M., et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007, 47:277-283.
93. Moreno C., Langlet P., Hittelet A., et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol 2010, 53:1117-1122.
94. Mezey E., Potter J.J., Rennie-Tankersley L., et al. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004, 40:40-46.
95. Mazer M., Perrone J. Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management. J Med Toxicol 2008, 4:2-6.
96. Lee W.M., Hynan L.S., Rossaro L., et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137:856-864.
97. Ngyen-Khac E.T.T., Piquet M.A., Benferhat S., et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N-acetylcysteine (C+NAC) versus corticoids alone (C): a multicenter randomized controlled trial [abstract]. Hepatology 2009, 50(Suppl):346A.
98. Bjarnason I., Peters T.J., Wise R.J. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984, 1:179-182.
99. Mandrekar P., Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol 2009, 50:1258-1266.
100. Liu Q., Duan Z.P., Ha D.K., et al. Symbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441-1449.
101. Zhao H.Y., Wang H.J., Lu Z., et al. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis 2004, 5:64-67.
102. Kirpich I.A., Solovieva N.V., Leikhter S.N., et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008, 42:675-682.
103. Stadlbauer V., Mookerjee R.P., Hodges S., et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008, 48:945-951.
104. Gillis J.C., Brogden R.N. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995, 49:467-484.
105. Vlachogiannakos J., Saveriadis A.S., Viazis N., et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009, 29:992-999.
106. Albillos A., de la Hera A., Gonzalez M., et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003, 37:208-217.
107. Rasaratnam B., Kaye D., Jennings G., et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003, 139:186-193.
108. Bird G.L., Prach A.T., McMahon A.D., et al. Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. J Hepatol 1998, 28:194-198.
109. Mezey E., Caballeria J., Mitchell M.C., et al. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled trial. Hepatology 1991, 14:1090-1096.
110. Trinchet J.C., Beaugrand M., Callard P., et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterol Clin Biol 1989, 13:551-555.
111. Trinchet J.C., Balkau B., Poupon R.E., et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992, 15:76-81.
112. Rambaldi A., Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2002, 2. CD002800.
113. Samara K., Liu C., Soldevila-Pico C., et al. Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation. Dig Dis Sci 2006, 51:1226-1229.
114. Jaeschke H. Neutrophil-mediated tissue injury in alcoholic hepatitis. Alcohol 2002, 27:23-27.
115. Morris J.M., Dickson S., Neilson M., et al. Granulocytapheresis in the treatment of severe alcoholic hepatitis: a case series. Eur J Gastroenterol Hepatol 2010, 22:457-460.
116. Spahr L., Lambert J.F., Rubbia-Brandt L., et al. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology 2008, 48:221-229.
117. Jalan R., Sen S., Steiner C., et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003, 38:24-31.
118. Sen S., Mookerjee R.P., Cheshire L.M., et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005, 43:142-148.
119. Kammuller M.E. Recombinant human interleukin-6: safety issues of a pleiotropic growth factor. Toxicology 1995, 105:91-107.
120. Ki SH, Park O, Zheng M, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology Oct;52:1291-300.
121. Seth D., Gorrell M.D., Cordoba S., et al. Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol 2006, 45:306-320.
122. Dominguez M., Miquel R., Colmenero J., et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 2009, 136:1639-1650.
123. Colmenero J., Bataller R., Sancho-Bru P., et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 2007, 132:687-697.
124. Morales O.D., Juez E., Moreno M., et al. Osteopontin is a novel therapeutic target in patients with alcoholic hepatitis. J Hepatol 2010, 52(Suppl 1):S23.
125. Tirnitz-Parker J.E., Viebahn C.S., Jakubowski A., et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology 2010, 52:291-302.
126. Whitfield K., Rambaldi A., Wetterslev J., et al. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009, 4. CD007339.
127. Neuberger J., Tang H. Relapse after transplantation: European studies. Liver Transpl Surg 1997, 3:275-279.
128. Neuberger J., Adams D., MacMaster P., et al. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. BMJ 1998, 317:172-175.
129. Anantharaju A.V.T. Liver transplantation for alcoholic liver disease 2004, National Institute of Alcohol Abuse and Alcoholism, Bethesda (MD).
130. Mackie J., Groves K., Hoyle A., et al. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transpl 2001, 7:418-427.
131. McCallum S., Masterton G. Liver transplantation for alcoholic liver disease: a systematic review of psychosocial selection criteria. Alcohol Alcohol 2006, 41:358-363.
132. Weinrieb R.M., Van Horn D.H., McLellan A.T., et al. Interpreting the significance of drinking by alcohol-dependent liver transplant patients: fostering candor is the key to recovery. Liver Transpl 2000, 6:769-776.
133. Pfitzmann R., Schwenzer J., Rayes N., et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2007, 13:197-205.
134. Lucey M.R., Brown K.A., Everson G.T., et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997, 3:628-637.
135. Mathurin P. Is alcoholic hepatitis an indication for transplantation?. Current management and outcomes. Liver Transpl 2005, (11 Suppl 2):S21-S24.
136. Dureja P., Lucey M.R. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol 2010, 52:759-764.
137. DiMartini A., Day N., Dew M.A., et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl 2006, 12:813-820.
138. Tome S., Martinez-Rey C., Gonzalez-Quintela A., et al. Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. J Hepatol 2002, 36:793-798.
139. Wells J.T., Said A., Agni R., et al. The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. Liver Transpl 2007, 13:1728-1735.
140. Shakil A.O., Pinna A., Demetris J., et al. Survival and quality of life after liver transplantation for acute alcoholic hepatitis. Liver Transpl Surg 1997, 3:240-244.
141. Immordino G., Gelli M., Ferrante R., et al. Alcohol abstinence and orthotopic liver transplantation in alcoholic liver cirrhosis. Transplant Proc 2009, 41:1253-1255.
142. Vanlemmens C., Di Martino V., Milan C., et al. Immediate listing for liver transplantation versus standard care for Child-Pugh stage B AC: a randomized trial. Ann Intern Med 2009, 150:153-161.